

ABC Pharma Ltd

Private & Confidential

Transaction Overview

- ABC Pharma Ltd is currently under Corporate Insolvency Resolution Process (CIRP).
- Sector: Pharmaceutical manufacturing, with legacy operations and regulatory approvals.
- Significant creditor exposure – JM Financial holds approximately 80–90% of the debt.
- Resolution Professional: Anshul Gupta | Contact: +91 77383 42001.
- Estimated enterprise valuation expectation: ₹400–500 Cr; EOI deposit: ₹7.5 Cr.

Asset & Business Overview

- One of India's legacy pharma players, active in manufacturing APIs and intermediates.
- Company historically operated multiple plants across India (likely Maharashtra, Gujarat).
- Net worth estimated at ₹100 Cr; actual asset value and operations to be verified during diligence.
- Potential interest for strategic pharma players, CDMOs, or fund-backed healthcare consolidators.
- Known names (as per outreach) include Shilpa Medicare, Ajanta Pharma, IPCA, and Arvind Remedies.

Company Operations & Infrastructure

Manufacturing Footprint:

- Historic presence across MIDC zones in **Tarapur, Mahad**, and possibly **Ankleshwar (Gujarat)**
- Multiple large-scale API/intermediate manufacturing facilities (subject to verification)
- Some units may be idle, leased, or non-operational during CIRP

Regulatory Licenses & Compliance:

- Previously held **GMP-compliant** manufacturing approvals
- Potential for revalidation of facilities under new ownership

Client Base & Products:

- Historically supplied to both domestic and regulated export markets
- Key product categories likely include **bulk drugs, intermediates, and APIs**
- Legacy relationships and dossiers may be available for transfer

Strategic Relevance:

- Ideal platform for a strategic pharma investor looking for infrastructure, licenses, or expansion into regulated markets
- Scope for CDMO repositioning, brownfield expansion, or API backward integration

Disclaimer

This teaser is prepared for a limited purpose only. The information contained herein is not intended to form the basis of any investment decision by prospective investors. Interested parties should carry out their own investigations and analysis of the company and of the data referred to in this document. This Document is distributed upon the express understanding that no information herein contained has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty expressed or implied is made that such information remains unchanged in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Document. Neither this document, nor anything contained herein, should form the basis of, or be relied upon in connection with any contract, agreement, undertaking, understanding or any commitment or investment decision whatsoever. Interested Parties should carry out independent due diligence with regards to the company.